• Can changes in EEG improve neuropathic pain treatments - read Oct newsletter.
  • Nine posters ready to reveal at the SfN virtual conference 8-11 Nov, booth 1818.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent

Schizophrenia Model

Transpharmation have extensive experience conducting research studies around the Schizophrenia Model. Our research has proven innovative for the development of medicines and more.

What is the Schizophrenia Model?

Schizophrenia is undoubtedly a debilitating disorder that affects approximately 1% of the worlds population. The disorder is categorised by ‘positive symptoms’, ‘negative symptoms’ and it's cognitive deficits.

Research into psychotic disorders such as schizophrenia involves multiple animal models as a tool for research and testing including in the pre-clinical development of drugs.

Patients with schizophrenia typically exhibit disturbances regarding information processing along with cognitive impairment. These disturbances are clinically investigated with different paradigms of auditory event related potentials (ERP) as well as by appropriate cognitive tests aligned to specific cognitive domains, recommended by MATRICS, CNTRIS and TURNS initiatives, which can be recapitulated in rodents.

Various models simulate schizophrenia defects. These models fit into four basic categories: pharmacological models, developmental models, lesion models, and genetic models. Typically, pharmacological / drug-induced models are the most commonly used.

At Transpharmation, our elegant electrophysiological approach enables detection of translational ERP endpoints such as N1 and MMN-like responses in standard and oddball paradigm stimuli in response to test compounds, benchmarked against NMDA antagonists, (ketamine, MK-801, PCP). Furthermore, our battery of rodent cognition tests provides the opportunity for assessing whether NCEs have the potential utility for treating a range of cognitive impairments associated with schizophrenia compared to atypical antipsychotics such as clozapine.

We also offer ‘classical models’ of positive symptoms, e.g amphetamine-evoked behaviour, using our advanced LABORAS home cage monitoring system.

Animals are often used as models for monitoring schizophrenia include rats, primates and mice. We primarily use mice due to our extensive experience in working with them.

sease relevant models we offer include the following:

  • Mismatch negativity (MMN)
  • Novel object recognition e.g. sub-chronic PCP-induced deficit
  • Reversal learning
  • Reversal of amphetamine/PCP-induced behaviours using LABORAS

schizophrenia model This list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.

Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk

Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design